Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC)
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that two poster presentations will be given at the 2016 European Breast Cancer Conference (EBCC), March 9-11 in Amsterdam, Netherlands. The studies looked at the use of the company’s MammaPrint 70-Gene Breast Cancer Recurrence assay in diagnostic testing as well as in large clinical studies, such as the MINDACT trial, the findings from which are expected to be presented later this year. MINDACT is a phase III, randomized, prospective study comparing the use of MammaPrint 70-gene assay with clinical-pathological criteria (current standard of care) for selecting early breast cancer patients who should be treated with adjuvant chemotherapy.
To inquire more about the MammaPrint performance data that will be presented at EBCC please visit Agendia booth 10.602. More details about EBCC can be found on the official EBCC website.
The company also announced it will be hosting a lunch symposium on Saturday March 12th entitled “Updates and Competitive Assessment of Genomic Assays and Their Clinical Relevance,” at the upcoming Miami Breast Cancer Conference (MBCC), March 10-13 in Miami, FL. The guest speaker for the symposium is James V. Pellicane, Jr., MD, FACS, who is the Director of Breast Cancer Oncology at the Bon Secours Cancer Institute in Richmond, VA.
To inquire more about the event that will be hosted at MBCC please visit Agendia booth 15. More details about MBCC can be found on the official MBCC website.
Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint® FFPE as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint®, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It is also a critical partner in the ISPY-2, NBRST and the MINDACT trials. For more information, visit www.agendia.com.
LifeSpring Life Sciences Communication
T +31 (0)6 538 16 427